Academic literature on the topic 'Brody disease'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Brody disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Brody disease"

1

Voermans, N. C., A. E. Laan, A. Oosterhof, T. H. van Kuppevelt, G. Drost, M. Lammens, E. J. Kamsteeg, et al. "Brody syndrome: A clinically heterogeneous entity distinct from Brody disease." Neuromuscular Disorders 22, no. 11 (November 2012): 944–54. http://dx.doi.org/10.1016/j.nmd.2012.03.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Braz, Luís, Ricardo Soares-dos-Reis, Mafalda Seabra, Fernando Silveira, and Joana Guimarães. "Brody disease: when myotonia is not myotonia." Practical Neurology 19, no. 5 (April 17, 2019): 417–19. http://dx.doi.org/10.1136/practneurol-2019-002224.

Full text
Abstract:
A 56-year-old man presented with painless impairment of muscle relaxation on vigorous contraction (eg, eyelid closure, hand grip, running). There were no episodes of paralysis, symptom progression, weakness or extramuscular symptoms. Five of his fifteen siblings had similar complaints. His serum creatine kinase was normal. Electromyography showed electrical silence on muscle relaxation, without myotonic discharges. DMPK, ClCN1 and SCN4A genetic testing was normal, but he had a homozygous pathogenic variant of ATP2A1 (c.1315G>A; pGlu439Lys). Brody disease is a rare autosomal recessive myopathy due to ATP2A1 mutations that reduce sarcoplasmic reticulum calcium-ATPase1 activity, hence delaying muscle relaxation.
APA, Harvard, Vancouver, ISO, and other styles
3

Molenaar, Joery P., Jamie I. Verhoeven, Richard J. Rodenburg, Erik J. Kamsteeg, Corrie E. Erasmus, Savine Vicart, Anthony Behin, et al. "Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients." Brain 143, no. 2 (February 1, 2020): 452–66. http://dx.doi.org/10.1093/brain/awz410.

Full text
Abstract:
Abstract Brody disease is an autosomal recessive myopathy characterized by exercise-induced muscle stiffness due to mutations in the ATP2A1 gene. Almost 50 years after the initial case presentation, only 18 patients have been reported and many questions regarding the clinical phenotype and results of ancillary investigations remain unanswered, likely leading to incomplete recognition and consequently under-diagnosis. Additionally, little is known about the natural history of the disorder, genotype-phenotype correlations, and the effects of symptomatic treatment. We studied the largest cohort of Brody disease patients to date (n = 40), consisting of 22 new patients (19 novel mutations) and all 18 previously published patients. This observational study shows that the main feature of Brody disease is an exercise-induced muscle stiffness of the limbs, and often of the eyelids. Onset begins in childhood and there was no or only mild progression of symptoms over time. Four patients had episodes resembling malignant hyperthermia. The key finding at physical examination was delayed relaxation after repetitive contractions. Additionally, no atrophy was seen, muscle strength was generally preserved, and some patients had a remarkable athletic build. Symptomatic treatment was mostly ineffective or produced unacceptable side effects. EMG showed silent contractures in approximately half of the patients and no myotonia. Creatine kinase was normal or mildly elevated, and muscle biopsy showed mild myopathic changes with selective type II atrophy. Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) activity was reduced and western blot analysis showed decreased or absent SERCA1 protein. Based on this cohort, we conclude that Brody disease should be considered in cases of exercise-induced muscle stiffness. When physical examination shows delayed relaxation, and there are no myotonic discharges at electromyography, we recommend direct sequencing of the ATP2A1 gene or next generation sequencing with a myopathy panel. Aside from clinical features, SERCA activity measurement and SERCA1 western blot can assist in proving the pathogenicity of novel ATP2A1 mutations. Finally, patients with Brody disease may be at risk for malignant hyperthermia-like episodes, and therefore appropriate perioperative measures are recommended. This study will help improve understanding and recognition of Brody disease as a distinct myopathy in the broader field of calcium-related myopathies.
APA, Harvard, Vancouver, ISO, and other styles
4

Guglielmi, V., N. C. Voermans, A. Oosterhof, D. Nowis, B. G. van Engelen, G. Tomelleri, and G. Vattemi. "Evidence of ER stress and UPR activation in patients with Brody disease and Brody syndrome." Neuropathology and Applied Neurobiology 44, no. 5 (July 18, 2018): 533–36. http://dx.doi.org/10.1111/nan.12431.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mussini, Jean-Marie, Armelle Magot, Daniel Hantaï, Damien Sternberg, Frédéric Chevessier, and Yann Péréon. "Atypical nuclear abnormalities in a patient with Brody disease." Neuromuscular Disorders 25, no. 10 (October 2015): 773–79. http://dx.doi.org/10.1016/j.nmd.2015.07.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Molenaar, J., J. Verhoeven, N. Voermans, J. Mathieu, G. Vattemi, J. Franques, T. Kuntzer, et al. "The Brody disease cohort study: clarification of the phenotype." Neuromuscular Disorders 27 (October 2017): S164. http://dx.doi.org/10.1016/j.nmd.2017.06.257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Guglielmi, Valeria, Gaetano Vattemi, Francesca Gualandi, Nicol C. Voermans, Matteo Marini, Chiara Scotton, Elena Pegoraro, et al. "SERCA1 protein expression in muscle of patients with Brody disease and Brody syndrome and in cultured human muscle fibers." Molecular Genetics and Metabolism 110, no. 1-2 (September 2013): 162–69. http://dx.doi.org/10.1016/j.ymgme.2013.07.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Voermans, N. C., A. E. Laan, A. Oosterhof, A. van Kuppevelt, G. Drost, M. Lammens, E. J. Kamsteeg, et al. "G.P.103 Brody syndrome: a clinically heterogeneous entity distinct from Brody disease: A review of literature and a cross-sectional clinical study in 17 patients." Neuromuscular Disorders 22, no. 9-10 (October 2012): 899. http://dx.doi.org/10.1016/j.nmd.2012.06.316.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vattemi, Gaetano, Francesca Gualandi, Arie Oosterhof, Matteo Marini, Paola Tonin, Paola Rimessi, Marcella Neri, et al. "Brody Disease: Insights Into Biochemical Features of SERCA1 and Identification of a Novel Mutation." Journal of Neuropathology & Experimental Neurology 69, no. 3 (March 2010): 246–52. http://dx.doi.org/10.1097/nen.0b013e3181d0f7d5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Burgio, Louis. "Interventions for the Behavioral Complications of Alzheimer's Disease: Behavioral Approaches." International Psychogeriatrics 8, S1 (October 1996): 45–52. http://dx.doi.org/10.1017/s1041610296003079.

Full text
Abstract:
A majority of patients with dementia of the Alzheimer type (DAT) display behavioral disturbances of varying degrees of severity. These disturbances include both behavioral excesses and deficits. The behavioral excesses reported in this population include physical aggression, wandering, and disruptive vocalization, to name but a few (Burgio et al., 1988b). Disruptive behaviors have been reported in at least 50% of individuals diagnosed with DAT (Cummings et al., 1987). Research has shown that individuals with dementia frequently display severe deficits in performing activities of daily living such as feeding, bathing, and dressing (Burgio et al., 1988b). Although these deficits are, in part, a natural result of the dementing illness, it has long been recognized by gerontologists that many demented individuals display “excess deficits” (Brody et al., 1971), i.e., symptoms of functional incapacity greater than those warranted by the actual organic impairment.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Brody disease"

1

GUGLIELMI, Valeria. "Biochemical features of SERCA1 in Brody disease and identication of candidate genes in Brody syndrome." Doctoral thesis, 2013. http://hdl.handle.net/11562/555349.

Full text
Abstract:
La malattia di Brody è una rara patologia muscolare che può essere trasmessa come carattere autosomico recessivo o dominante. L'ereditarietà recessiva è associata a mutazione del gene ATP2A1 che codifica la proteina del reticolo sarcoplasmico/endoplasmico calcio ATPasi 1 (SERCA1), la quale catalizza il riassorbimento ATP-dipendente del Ca2+ dal citosol al lume del reticolo sarcoplasmatico. Tuttavia, mutazioni nel gene ATP2A1 non sono state identificate in alcuni pazienti con ereditarietà recessiva ed in tutti i casi che presentano la forma autosomica dominante, suggerendo l'eterogeneità genetica della malattia. Il termine “sindrome di Brody” è stato recentemente proposto per designare pazienti con ridotta attività SR Ca2+-ATPasica ma senza mutazioni del gene ATP2A1. La principale caratteristica clinica è il ritardo nel rilassamento muscolare a seguito dell’ esercizio con conseguente rigidità muscolare in assenza di dolore. La creatina chinasi (CK) sierica è normale o leggermente aumentata, l'elettromiografia (EMG) registra scariche pseudo-miotoniche durante gli episodi di rigidità muscolare indotta da esercizio ("silent cramps") ed il fenomeno miotonico non è presente. Una ridotta attività SR Ca2+-ATPasica è stata riportata in tutti i casi descritti, indipendentemente dall’associazione con mutazioni di ATP2A1. Al contrario, i dati sull’ espressione della proteina SERCA1 sono ancora oggetto di dibattito. Infatti, nei muscoli dei pazienti con BD, mediante immunoistochimica è stata riportata una normale o ridotta espressione di SERCA1, mentre l’immunoblot, effettuato solo in pochi casi, ha documentato una significativa riduzione dei livelli di espressione di SERCA1. Nella prima parte di questo studio sono stati caratterizzati 13 pazienti con miopatia di Brody tramite analisi molecolare e biochimica condotte sul muscolo scheletrico. Mediante immunofluorescenza, SERCA1 ha mostrato una distribuzione ed un’ intensità di segnale simili nel muscolo dei controlli e dei pazienti con e senza mutazione di ATP2A1 mentre, inaspettatamente, l’immunoblot dopo SDS-PAGE e 2D-PAGE ha mostrato una significativa riduzione di espressione di SERCA1 nei muscoli dei pazienti con BD rispetto ai muscoli dei pazienti con BS e dei soggetti di controllo. Pertanto è stato ipotizzato che la proteina mutata potesse avere una diversa solubilità di quella wild type. Tuttavia, la resa di estrazione di SERCA1 mutata era inferiore a quello della proteina wild-type, indipendentemente dal tampone di lisi utilizzato, suggerendo che le mutazioni identificate non influenzino le proprietà di solubilità della proteina SERCA1 nei tamponi usati per omogenare il muscolo. Lo studio dello stato di oligomerizzazione della proteina ha mostrato uno spostamento dalle forme monometrica/dimerica allo stato oligomerico ad alto peso molecolare di SERCA1 nel muscolo dei pazienti con mutazione di ATP2A1, fornendo una possibile spiegazione della riduzione del livello di SERCA1 allo stato monomerico riscontrato all’immunoblot dopo SDS-PAGE. Questi dati evidenziano inoltre come l’immunoblot, contrariamente all’immunoistochimica, possa essere utile per la diagnosi della malattia di Brody in pazienti con ridotta attività SR Ca2+-ATPasica. In questo studio è stata anche riportata la caratterizzazione clinica ed istologica di un nuovo paziente con sindrome di Brody e sono state documentate due nuove mutazioni nel gene ATP2A1 in un nuovo paziente e in un caso di malattia Brody precedentemente descritto. Lo studio di localizzazione di SERCA1 nel reticolo sarcoplasmatico non ha mostrato differenze tra il muscolo dei pazienti con BD e quelli con BS. Nella seconda parte dello studio è stata valutata l'espressione delle isoforme di SERCA1 e saggiata l’attività SR Ca2+-ATPasica nei muscoli dei pazienti con distrofia miotonica (tipo 1 e 2) e dei pazienti con miopatia ipotiroidea. Infatti, i dati di letteratura supportavano l’ipotesi di un’ alterata espressione di SERCA1 e di una ridotta attività del SR Ca2+-ATPasica nel muscolo nei pazienti con distrofia miotonica e nei modelli murini di ipotiroidismo. In questo studio non sono stati osservate nè una riduzione dell’attività SR Ca2+-ATPasica nè una ridotta espressione di SERCA1 e SERCA2 nei muscoli dei pazienti affetti da distrofia miotonica e di quelli con miopatia ipotiroidea. Nel muscolo di pazienti affetti da distrofia miotonica è stata documentata la presenza dell’isoforma neonatale SERCA1b, i cui livelli di espressione sono risultati essere maggiori nel muscolo dei pazienti con distrofia miotonica di tipo 2 rispetto ai pazienti affetti da distrofia miotonica di tipo 1. Inoltre, in questo studio è stata analizzata l’espressione di SERCA1 e SERCA2 nel muscolo di neonati a diversi stadi di sviluppo (10, 20 giorni, uno e quattro mesi dopo la nascita). In tutti gli stadi di sviluppo neonatale analizzati, l’espressione di SERCA1 era presente solo in alcune fibre, mentre la quasi totalità delle fibre muscolari esprimeva SERCA2 fino ad 1 mese dopo la nascita. Nel muscolo dei neonati di 10 e 20 giorni, solo poche fibre presentavano SERCA1b. Infine, è stato dimostrato che SERCA1b è la principale isoforma di SERCA1 espressa, insieme con SERCA2, in colture primarie di muscolo scheletrico umano le quali rappresentano quindi un buon modello per lo studio del muscolo nelle prime fasi dello sviluppo neonatale. Nella terza e ultima parte di questo studio sono state identificate nuove proteine che interagiscono in condizioni fisiologiche con SERCA1 e che potrebbero pertanto rappresentare geni candidati responsabili della sindrome di Brody. Infatti, la mutazione in un gene codificante una proteina che, interagendo con SERCA1 è in grado di regolarne la funzione potrebbe spiegare la riduzione dell’attività SR Ca2+-ATPasica nei pazienti senza mutazione in ATP2A1. Due diversi approcci sono stati usati per identificare nuovi partners di legame di SERCA1. La purificazione mediante affinità accoppiata a spettrometria di massa ha portato ad identificare la proteina del reticolo sarcoplasmico/endoplasmico calcio ATPasi 3 (SERCA3) come proteina di legame di SERCA1. L'espressione delle isoforme di SERCA3 nel muscolo scheletrico ha mostrato che SERCA3b è presente nelle fibre muscolari di tipo 2, le stesse che esprimono SERCA1. Inoltre, esperimenti di elettroforesi nativa/SDS-PAGE e di co-immunoprecipitazione hanno confermato la possibile interazione tra SERCA1 e SERCA3b nel muscolo scheletrico in condizioni fisiologiche. Il secondo approccio è stato quello di isolare i complessi SERCA1-proteina allo stato nativo dal muscolo scheletrico e di identificare le proteine di legame di SERCA1 mediante spettrometria di massa. Questa strategia ha portato all’identificazione di sarcalumenina, di reticulone-2, di Nogo/reticulone-4 e di mioadenilato deaminasi come possibili proteine che interagiscono con SERCA1. Una riduzione dell'espressione di sarcalumenina è stata osservata nel muscolo di quattro pazienti con sindrome di Brody, suggerendo SLN come un gene candidato per la malattia.
Brody disease is a rare skeletal muscle disorder transmitted as an autosomal recessive or dominant trait. The recessive inheritance is associated to mutation of ATP2A1 gene encoding the sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1), a protein that catalyzes the ATP dependent Ca2+ uptake from the cytosol to the lumen of sarcoplasmic reticulum. However, mutations in the ATP2A1 gene are missed in some patients with recessive inheritance and have never been found in patients with an autosomal dominant pattern suggesting the genetic heterogeneity of the disease. The term Brody syndrome has been recently proposed to designate patients with decreased SR Ca2+ATPase activity but without ATP2A1 mutation. The main clinical feature is the exercise-induced delay in muscle relaxation which causes painless muscle stiffness following contraction. Serum creatine kinase (CK) is normal or slightly increased, needle electromyography (EMG) records no myotonic and pseudomyotonic discharges during the exercise-induced muscle stiffness (“silent cramps”) and percussion myotonia is absent. Reduction of SR Ca2+ ATPase activity has been reported in all described cases, independently from the association with ATP2A1 mutation. Conversely, data on SERCA1 protein expression are still under debate. Indeed, in muscle of patients with BD, immunostaining for SERCA1 has been reported to be normal or reduced while immunoblot analysis,performed in just a few cases, documented a significant reduction in protein amount. In the first part of the study we performed molecular and biochemical analysis on muscle from 13 patients with Brody myopathy. Immunofluorescence studies of SERCA1 revealed similar staining pattern and intensity in muscle of controls and of patients with and without ATP2A1 mutation whereas, contrary to the expectations, immunoblot analysis after SDS-PAGE and 2D gel electrophoresis showed a significant reduction of SERCA1 protein in muscle of patients with BD as compared to muscle of patients with BS and of control subjects. Therefore, we hypothesized that the mutated protein could have different solubility features of the wild type one. However, the recovery of mutated SERCA1 was lower than that of the wild type protein, irrespectively the lysis buffer, suggesting that mutations detected in ATP2A1 gene did not affect the solubility properties of SERCA1 in the buffers we used for muscle homogenization The study of SERCA1 oligomerization revealed the shift from monomeric/dimeric forms to the high-oligomeric status of SERCA1 in muscle from patients with ATP2A1 mutation, providing a possible explanation of the reduced detection of SERCA1 monomer after denaturing electrophoresis. The present data provide also evidence that immunoblotting, in contrast to the immunohistochemistry, could be a useful tool for confirming the diagnosis of BD in patients with reduced SR Ca2+ ATPase activity. In this study we reported also the clinical and histological characterization of a new patient with Brody syndrome and document novel mutations in the ATP2A1 gene of a new patient and in a previously described case of Brody disease. Moreover, we study SERCA1 distribution within the sarcoplasmic reticulum revealing no remarkable changes in the localization of the protein in muscle from patients with BD and BS. In the second part of the study we analyzed the expression of SERCA1 isoforms and investigated SR Ca2+ ATPase activity in muscle of patients with myotonic dystrophy (type 1 and 2) and in hypothyroid myopathy. Indeed, data from the literature seem to support the alteration of SERCA1 expression and SR Ca2+ ATPase activity in patients with myotonic dystrophies and in hypothyroid mice. We observed no significant changes in SR Ca2+ ATPase activity, SERCA1 and SERCA2 expression in muscle from patients with myotonic dystrophies and with hypothyroid myopathy. Interestingly, we observed that the neonatal isoform SERCA1b is expressed in myotonic dystrophies, in particular at higher levels in type 2 than type 1 disease. Moreover, we provide data on SERCA1 and SERCA2 expression in neonatal muscle at different developmental stages (10, 20 days, one and four months after birth) revealing that, at all analyzed time of neonatal development, SERCA1 is expressed only in some fibers whereas nearly all fibers express SERCA2 up to 1 month after birth. In muscle from 10 and 20 days after birth, only a few fibers express SERCA1b. Finally, we showed that SERCA1b is the main SERCA1 isoforms expressed, together with SERCA2, in cultured human muscle fibers which therefore represent a good model to study neonatal muscle at early stages after birth. In the third, and last part of this study we focused on the identification of novel physiological interacting partners of SERCA1 that could be candidate genes responsible for Brody syndrome. Indeed, mutation in a gene encoding a protein which, by interacting with SERCA1, is able to regulate its function could account for the decreased SR Ca2+ ATPase activity in patients without ATP2A1 mutations. Two different approaches were used to identify novel SERCA1 binding partners. Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (SERCA3) has been identified as a reliable SERCA1-binding protein by affinity purification couple to mass spectrometry. The analysis of SERCA3 isoforms expression in skeletal muscle tissue led to identify SERCA3b as strongly expressed in type 2 muscle fibers, where SERCA1 is also located. Moreover, native/SDS-PAGE and co-immunoprecipitation experiments seem to support the existence of an interaction between SERCA1 and SERCA3b in skeletal muscle in physiological conditions. The second approach consisted in isolating SERCA1-protein complexes in native state from skeletal muscle and in protein identification by mass spectrometry. This strategy led to the identification of sarcalumenin, reticulon-2, Nogo/reticulon-4 and myoadenylate deaminase as putative SERCA1 interacting partners. A reduction of sarcalumenin expression was observed in muscle from four patients with Brody syndrome suggesting SLN gene as a candidate gene the disease.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Brody disease"

1

Brady Urology Manual. Informa Healthcare, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Parsons, J. Kellogg, and E. James Wright. Brady Urology Manual. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Parsons, J. Kellogg, and E. James Wright. Brady Urology Manual. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Parsons, J. Kellogg, and E. James Wright. Brady Urology Manual. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Parsons, J. Kellogg, and E. James Wright. Brady Urology Manual. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Parsons, J. Kellogg, and E. James Wright. Brady Urology Manual. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Brody disease"

1

Angelini, Corrado. "Brody Disease." In Genetic Neuromuscular Disorders, 235–38. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56454-8_62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Angelini, Corrado. "Brody Disease." In Genetic Neuromuscular Disorders, 199–202. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-07500-6_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jungbluth, Heinz. "Core Myopathies, Malignant Hyperthermia Susceptibility, and Brody Disease." In Muscle Disease, 214–24. Oxford, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118635469.ch23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Brody Disease (ATP2A1)." In Encyclopedia of Genetics, Genomics, Proteomics and Informatics, 240. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6754-9_2060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bivalacqua, Trinity J., and Mohamad E. Allaf. "Erectile dysfunction and Peyronie’s disease." In The Brady Urology Manual, 51–62. CRC Press, 2019. http://dx.doi.org/10.1201/9780429194993-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Varkarakis, Ioannis M. "Cystic diseases of the kidney." In The Brady Urology Manual, 107–14. CRC Press, 2019. http://dx.doi.org/10.1201/9780429194993-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Parsons, J. Kellogg. "Diseases of the adrenal gland." In The Brady Urology Manual, 195–206. CRC Press, 2019. http://dx.doi.org/10.1201/9780429194993-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Balaji, Seshadri, Ravi Mandapati, and Gary D. Webb. "Fontan Patient With Brady and Tachyarrhythmia Issues." In Arrhythmias in Adult Congenital Heart Disease, 77–91. Elsevier, 2019. http://dx.doi.org/10.1016/b978-0-323-48568-5.00010-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Balaji, Seshadri, Ravi Mandapati, and Gary D. Webb. "A Crisscross Heart With Brady-Tachy Issues." In Arrhythmias in Adult Congenital Heart Disease, 135–48. Elsevier, 2019. http://dx.doi.org/10.1016/b978-0-323-48568-5.00015-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Balaji, Seshadri, Ravi Mandapati, and Gary D. Webb. "Transposition Patient With Mustard's Operation and Brady-Tachy Issues." In Arrhythmias in Adult Congenital Heart Disease, 121–33. Elsevier, 2019. http://dx.doi.org/10.1016/b978-0-323-48568-5.00014-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography